Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 3/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 4/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393877 | 1.00 | CYP1A1 (0.47) | CYP1A1CYP1B1ALDH1A1CYP2A6NQO2 | |
| SCHEMBL3194836 | 0.90 | PIM1 (0.36) | ALDH1A1CYP2A6 | |
| SCHEMBL18002962 | 0.85 | NQO2 (0.46) | CYP1A1CYP1B1NQO2ESR1CYP1A2 | |
| SCHEMBL228003 | 0.84 | CYP1A1 (0.64) | CYP1A1CYP1B1ALDH1A1CYP2A6NQO2 | |
| SCHEMBL1048346 | 0.84 | ALDH1A1 (0.58) | CYP1A1CYP1B1ALDH1A1CYP2A6NQO2 | |
| Water SCHEMBL28227114 | 0.82 | CYP1A1 (0.61) | CYP1A1CYP1B1ALDH1A1CYP2A6NQO2 | |
| SCHEMBL16955225 | 0.81 | CYP1A1 (0.47) | CYP1A1CYP1B1ALDH1A1NQO2ESR1 | |
| SCHEMBL16950419 | 0.81 | CYP1A1 (0.47) | CYP1A1CYP1B1ALDH1A1NQO2ESR1 | |
| SCHEMBL2600018 | 0.81 | PTGS1 (0.46) | CYP1A1CYP1B1ALDH1A1CYP2A6NQO2 | |
| SCHEMBL29490987 | 0.81 | PTGS1 (0.46) | CYP1A1CYP1B1ALDH1A1CYP2A6NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584266-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052701-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| EP-3383873-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECH LTD (GB) | 2022-03-09 | — | — | EP | disclosed |
| CN-108349966-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-08-12 | — | — | US | disclosed |
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-08-12 | — | — | US | disclosed |
| US-10981904-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| EP-3383873-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017093299-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017093299-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
| US-20170152255-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152255-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152255-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| EP-0719253-B1 | 3-AMINO-5-CARBOXY-SUBSTITUTED PIPERIDINES AND 3-AMINO-4-CARBOXY-SUBSTITUTED PYRROLIDINES AS TACHYKININ ANTAGONISTS | PFIZER (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6083943-A | FOR TREATMENT OF GASTROINTESTINAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, ALLERGY, INFLAMMATORY DISEASES, ASTHMA, PAIN, EMESIS OR MIGRAINE IN MAMMALS, ESPECIALLY HUMANS | PFIZER INC (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0719253-A1 | 3-AMINO-5-CARBOXY-SUBSTITUTED PIPERIDINES AND 3-AMINO-4-CARBOXY-SUBSTITUTED PYRROLIDINES AS TACHYKININ ANTAGONISTS | PFIZER INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007886-A1 | 3-AMINO-5-CARBOXY-SUBSTITUTED PIPERIDINES AND 3-AMINO-4-CARBOXY-SUBSTITUTED PYRROLIDINES AS TACHYKININ ANTAGONISTS | PFIZER INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152255-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | GLS2, GLS, GLUL | CYP1A1 855/4885CYP1B1 824/4885ALDH1A1 233/4885 |
| US-10981904-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLUL | CYP1A1 855/4885CYP1B1 824/4885ALDH1A1 233/4885 |
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | GLS2, GLS, GLUL | CYP1A1 855/4885CYP1B1 824/4885ALDH1A1 233/4885 |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLUL | CYP1A1 855/4885CYP1B1 824/4885ALDH1A1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.